IMVT (Immunovant, Inc.) Stock Market Reviews

crown

search

Read and share opinions on IMVT (Immunovant, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

IMVT

Immunovant, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Nov 11, 2025
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Nov 10, 2025
Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation?
Nov 3, 2025
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results
Oct 31, 2025
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Oct 27, 2025
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37
Oct 8, 2025
Where is Immunovant (IMVT) Heading According to Analysts?
Sep 30, 2025
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
Sep 10, 2025
A Look at Immunovant's Valuation Following New Batoclimab Data Update for Graves' Disease
Sep 9, 2025
Immunovant's New Data Shows Batoclimab's Potential to Replace Current Graves' Disease Options, Oppenheimer Says
Sep 4, 2025
Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise
Sep 3, 2025
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
Aug 12, 2025

Reviews